Literature DB >> 2297848

Serum aminoterminal type III procollagen peptide reflects repair after acute myocardial infarction.

L T Jensen1, K Hørslev-Petersen, P Toft, K D Bentsen, P Grande, E E Simonsen, I Lorenzen.   

Abstract

In 16 patients with acute myocardial infarction and in 15 controls, procollagen type III aminoterminal peptide in serum (PIIINP) was measured consecutively. Serum PIIINP was increased on the second to third postinfarction day (p less than 0.01) and remained elevated for more than 4 months. Peak values were observed on the third to seventh postinfarction day. The individual peak changes were correlated to infarction size calculated from serum CK-MB and serum lactate dehydrogenase (p = 0.60, p = 0.02). The changes in distribution of PIIINP-related antigens in serum after gel chromatography were similar to changes observed during wound healing in humans. PIIINP is cleaved off procollagen type III during the biosynthesis of type III collagen, which characterizes the early stages of repair and inflammation. Our findings suggest that serum PIIINP reflects the repair processes and scar formation following acute myocardial infarction. The serum PIIINP alterations in acute myocardial infarction differ essentially from the changes in myocardial enzymes reflecting myocardial injury. Serum PIIINP may therefore provide new and clinically relevant information on the healing of myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297848     DOI: 10.1161/01.cir.81.1.52

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  11 in total

1.  Time course of plasma markers of collagen turnover in patients with acute myocardial infarction.

Authors:  A D McGavigan; J Moncrieff; M M Lindsay; P R Maxwell; F G Dunn
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

2.  Changes in collagen metabolites in serum after cemented hip and knee arthroplasty.

Authors:  S Joerring; L T Jensen
Journal:  Arch Orthop Trauma Surg       Date:  1993       Impact factor: 3.067

3.  Quantitative assessment of the age of fibrotic lesions using polarized light microscopy and digital image analysis.

Authors:  J G Pickering; D R Boughner
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

Review 4.  Biomarkers: optimizing treatment guidance in heart failure.

Authors:  Michael Böhm; Adriaan A Voors; Jean-Marie Ketelslegers; Stephan H Schirmer; Eva Turgonyi; Peter Bramlage; Faiez Zannad
Journal:  Clin Res Cardiol       Date:  2011-07-16       Impact factor: 5.460

5.  Fibrosis-related biomarkers and risk of total and cause-specific mortality: the cardiovascular health study.

Authors:  Isha Agarwal; Nicole L Glazer; Eddy Barasch; Mary L Biggs; Luc Djoussé; Annette L Fitzpatrick; John S Gottdiener; Joachim H Ix; Jorge R Kizer; Eric B Rimm; David S Siscovick; Russell P Tracy; Susan J Zieman; Kenneth J Mukamal
Journal:  Am J Epidemiol       Date:  2014-04-25       Impact factor: 4.897

Review 6.  MMP induction and inhibition in myocardial infarction.

Authors:  Merry L Lindsey
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

Review 7.  Extracellular matrix fibrotic markers in heart failure.

Authors:  Faiez Zannad; Patrick Rossignol; Wafae Iraqi
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

Review 8.  Cardiac biomarkers in children with congenital heart disease.

Authors:  Masaya Sugimoto; Seiko Kuwata; Clara Kurishima; Jeong Hye Kim; Yoich Iwamoto; Hideaki Senzaki
Journal:  World J Pediatr       Date:  2015-10-11       Impact factor: 2.764

9.  Procollagen type III N-terminal peptide (P3NP) and lean mass: a cross-sectional study.

Authors:  Sarah D Berry; Vasan S Ramachandran; Peggy M Cawthon; Philimon Gona; Robert R McLean; L Adrienne Cupples; Douglas P Kiel
Journal:  J Frailty Aging       Date:  2013

Review 10.  Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers.

Authors:  Camelia R Ban; Stephen M Twigg
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.